Hosted on MSN10d
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the WorldAscentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...
Ascentage Pharma Group International ( ($HK:6855) ) has provided an announcement. Ascentage Pharma Group International ...
GlobalData on MSN13d
Ascentage Pharma raises $126m in first biotech IPO of 2025The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial ...
Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross ...
Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Ascentage Pharma Group International (Nasdaq: AAPG), a global ...
Investing.com-- Ascentage Pharma Group International (HK: 6855) shares plunged on Friday in Hong Kong trading, as investors ...
Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback